Lautenbach A - Search Results

1

Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure.

Lautenbach A, Kantowski T, Wagner J, Mann O, Stoll F, Aberle J. Lautenbach A, et al. Clin Obes. 2023 Oct;13(5):e12593. doi: 10.1111/cob.12593. Epub 2023 Jun 26. Clin Obes. 2023. PMID: 37364260

2

Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells.

Lautenbach A, Budde A, Wrann CD, Teichmann B, Vieten G, Karl T, Nave H. Lautenbach A, et al. Nutr Cancer. 2009;61(4):484-91. doi: 10.1080/01635580802610115. Nutr Cancer. 2009. PMID: 19838920

3

Human obesity reduces the number of hepatic leptin receptor (ob-R) expressing NK cells.

Lautenbach A, Breitmeier D, Kuhlmann S, Nave H. Lautenbach A, et al. Endocr Res. 2011;36(4):158-66. doi: 10.3109/07435800.2011.580442. Endocr Res. 2011. PMID: 21973235

4

[Obesity - a chronic disease requiring treatment].

Meyhöfer S, Lautenbach A, Serfling G. Meyhöfer S, et al. Among authors: lautenbach a. Dtsch Med Wochenschr. 2022 Jun;147(11):656-662. doi: 10.1055/a-1657-2047. Epub 2022 May 30. Dtsch Med Wochenschr. 2022. PMID: 35636415 German.

5

[Adipositas - new aspects in internistic care before and after bariatric surgery].

Zur Wiesch CS, Lautenbach A, Aberle J. Zur Wiesch CS, et al. Among authors: lautenbach a. Dtsch Med Wochenschr. 2016 Sep;141(20):1437-1440. doi: 10.1055/s-0042-112081. Epub 2016 Oct 4. Dtsch Med Wochenschr. 2016. PMID: 27701686 Review. German.

6

Development of Obesity-Associated Comorbidities Post Bariatric Surgery with a Special Focus on Diabetes Remission and Short-Term Relapse.

Riedel N, Lautenbach A, Wienecke JW, Mann O, Flitsch J, Aberle J. Riedel N, et al. Among authors: lautenbach a. Exp Clin Endocrinol Diabetes. 2018 Sep;126(9):577-583. doi: 10.1055/s-0043-119985. Epub 2017 Nov 8. Exp Clin Endocrinol Diabetes. 2018. PMID: 29117619

7

Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).

Riedel N, Laubner K, Lautenbach A, Schön G, Schlensak M, Stengel R, Eberl T, Dederichs F, Aberle J, Seufert J. Riedel N, et al. Among authors: lautenbach a. Obes Surg. 2018 Aug;28(8):2187-2196. doi: 10.1007/s11695-018-3144-9. Obes Surg. 2018. PMID: 29504053

8

Specificity of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay for Cushing's disease in an obese population.

Aberle J, Schulze Zur Wiesch C, Flitsch J, Veigel J, Schön G, Jung R, Reining F, Lautenbach A, Rotermund R, Riedel N. Aberle J, et al. Among authors: lautenbach a. J Endocrinol Invest. 2018 Nov;41(11):1325-1331. doi: 10.1007/s40618-018-0870-8. Epub 2018 Mar 17. J Endocrinol Invest. 2018. PMID: 29550934

9

Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study.

Laubner K, Riedel N, Fink K, Holl RW, Welp R, Kempe HP, Lautenbach A, Schlensak M, Stengel R, Eberl T, Dederichs F, Schwacha H, Seufert J, Aberle J. Laubner K, et al. Among authors: lautenbach a. Diabetes Obes Metab. 2018 Aug;20(8):1868-1877. doi: 10.1111/dom.13300. Epub 2018 Apr 23. Diabetes Obes Metab. 2018. PMID: 29569313

10

Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner.

Riedel N, Laubner K, Lautenbach A, Schön G, Schlensak M, Stengel R, Eberl T, Dederichs F, Aberle J, Seufert J. Riedel N, et al. Among authors: lautenbach a. Surg Obes Relat Dis. 2018 Jun;14(6):769-779. doi: 10.1016/j.soard.2018.02.029. Epub 2018 Mar 9. Surg Obes Relat Dis. 2018. PMID: 29650340

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page